SALL4 oncogene is an immunogenic antigen presented in various HLA-DR contexts

References

• Frei E, Schuh R, Baumgartner S, Burri M, Noll M, Jürgens G, Seifert E, Nauber U, Jäckle H. Molecular characterization of spalt, a homeotic gene required for head and tail development in the Drosophila embryo. EMBO J. 1988;7(1):197–204.
   PubMed Web of Science ®Google Scholar
• Jürgens G. Head and tail development of the Drosophila embryo involves spalt, a novel homeotic gene. EMBO J. 1988;7(1):189–96.
   PubMed Web of Science ®Google Scholar
• Sweetman D, Münsterberg A. The vertebrate spalt genes in development and disease. Dev Biol. 2006; 293(2):285–93. doi:10.1016/j.ydbio.2006.02.009.
   PubMed Web of Science ®Google Scholar
• Kohlhase J, Schuh R, Dowe G, Kühnlein RP, Jäckle H, Schroeder B, Schulz-Schaeffer W, Kretzschmar HA, Köhler A, Müller U, et al. Isolation, Characterization, and Organ-Specific Expression of Two Novel Human Zinc Finger Genes Related to theDrosophilaGenespalt. Genomics. 1996;38(3):291–8. doi:10.1006/geno.1996.0631.
   PubMed Web of Science ®Google Scholar
• Gao C, Kong NR, Li A, Tatetu H, Ueno S, Yang Y, He J, Yang J, Ma Y, Kao GS, et al. SALL4 is a key transcription regulator in normal human hematopoiesis. Transfusion. 2013;53(5):1037–49. doi:10.1111/j.1537-2995.2012.03888.x.
   PubMed Web of Science ®Google Scholar
• Yang J, Chai L, Gao C, Fowles TC, Alipio Z, Dang H, Xu D, Fink LM, Ward DC, Ma Y. SALL4 is a key regulator of survival and apoptosis in human leukemic cells. Blood.2008; 112(3):805–13. doi:10.1182/blood-2007-11-126326.
   PubMed Web of Science ®Google Scholar
• Xiong J. SALL4: engine of cell stemness. Curr Gene Ther. 2014;14(5):400–11. doi:10.2174/1566523214666140825125138.
   PubMed Web of Science ®Google Scholar
• Ma Y, Cui W, Yang J, Qu J, Di C, Amin HM, Lai R, Ritz J, Krause DS, Chai L. SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood. 2006;108(8):2726–35. doi:10.1182/blood-2006-02-001594.
   PubMed Web of Science ®Google Scholar
• Camparo P, Comperat EM. SALL4 is a useful marker in the diagnostic work-up of germ cell tumors in extra-testicular locations. Virchows Arch Int J Pathol. 2013;462(3):337–41. doi:10.1007/s00428-012-1353-5.
   PubMed Web of Science ®Google Scholar
• Kobayashi D, Kuribayashi K, Tanaka M, Watanabe N. Overexpression of SALL4 in lung cancer and its importance in cell proliferation. Oncol Rep. 2011;26(4):965–70.
   PubMed Web of Science ®Google Scholar
• Yong KJ, Gao C, Lim JSJ, Yan B, Yang H, Dimitrov T, Kawasaki A, Ong CW, Wong K-F, Lee S, et al. Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. N Engl J Med. 2013;368(24):2266–76. doi:10.1056/NEJMoa1300297.
   PubMed Web of Science ®Google Scholar
• Zhang L, Xu Z, Xu X, Zhang B, Wu H, Wang M, Zhang X, Yang T, Cai J, Yan Y, et al. SALL4, a novel marker for human gastric carcinogenesis and metastasis. Oncogene. 2014; 33(48):5491–500. doi:10.1038/onc.2013.495.
   PubMed Web of Science ®Google Scholar
• Cao D, Li J, Guo CC, Allan RW, Humphrey PA. SALL4 is a novel diagnostic marker for testicular germ cell tumors. Am J Surg Pathol. 2009;33(7):1065–77. doi:10.1097/PAS.0b013e3181a13eef.
   PubMed Web of Science ®Google Scholar
• Ardalan Khales S, Abbaszadegan MR, Abdollahi A, Raeisossadati R, Tousi MF, Forghanifard MM. SALL4 as a new biomarker for early colorectal cancers. J Cancer Res Clin Oncol. 2015;141(2):229–35. doi:10.1007/s00432-014-1808-y.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang L, Yang A, Jiang P, Wang M. Up-regulation of SALL4 associated with poor prognosis in gastric cancer. Hepatogastroenterology. 2014;61(133):1459–64.
   PubMedGoogle Scholar
• Cui W, Kong NR, Ma Y, Amin HM, Lai R, Chai L. Differential expression of the novel oncogene, SALL4, in lymphoma, plasma cell myeloma, and acute lymphoblastic leukemia. Mod Pathol Off J U S Can Acad Pathol Inc. 2006;19(12):1585–92.
   PubMed Web of Science ®Google Scholar
• Li A, Jiao Y, Yong KJ, Wang F, Gao C, Yan B, Srivastava S, Lim GSD, Tang P, Yang H, et al. SALL4 is a new target in endometrial cancer. Oncogene. 2015;34(1):63–72. doi:10.1038/onc.2013.529.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang J, Yang X, Fang C, Xu H, Xi X. SALL4 as an Epithelial-Mesenchymal Transition and Drug Resistance Inducer through the Regulation of c-Myc in Endometrial Cancer. PloS One. 2015;10(9):e0138515. doi:10.1371/journal.pone.0138515.
   PubMed Web of Science ®Google Scholar
• Yanagihara N, Kobayashi D, Kuribayashi K, Tanaka M, Hasegawa T, Watanabe N. Significance of SALL4 as a drug-resistant factor in lung cancer. Int J Oncol. 2015;46(4):1527–34. doi:10.3892/ijo.2015.2866.
   PubMed Web of Science ®Google Scholar
• Chen Y-Y, Li Z-Z, Ye Y-Y, Xu F, Niu R-J, Zhang H-C, Zhang Y-J, Liu Y-B, Han B-S. Knockdown of SALL4 inhibits the proliferation and reverses the resistance of MCF-7/ADR cells to doxorubicin hydrochloride. BMC Mol Biol. 2016;17:6. doi:10.1186/s12867-016-0055-y.
   PubMed Web of Science ®Google Scholar
• Tatetsu H, Kong NR, Chong G, Amabile G, Tenen DG, Chai L. SALL4, the missing link between stem cells, development and cancer. Gene. 2016;584(2):111–19. doi:10.1016/j.gene.2016.02.019.
   PubMed Web of Science ®Google Scholar
• Cheng J, Gao J, Shuai X, Tao K. Oncogenic protein SALL4 and ZNF217 as prognostic indicators in solid cancers: a meta-analysis of individual studies. Oncotarget. 2016;7(17):24314–25. doi:10.18632/oncotarget.8237.
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17):5323–37. doi:10.1158/1078-0432.CCR-09-0737.
   PubMed Web of Science ®Google Scholar
• Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, Hasz R, Walters G, Garcia F, Young N, et al. The Genotype-Tissue Expression (GTEx) project. Nat Genet 2013;45(6): 580–5. doi:10.1038/ng.2653.
   PubMed Web of Science ®Google Scholar
• Lu J, Ma Y, Kong N, Alipio Z, Gao C, Krause DS, Silberstein LE, Chai L. Dissecting the role of SALL4, a newly identified stem cell factor, in chronic myelogenous leukemia. Leukemia 2011;25(7):1211–3. doi:10.1038/leu.2011.65.
   PubMed Web of Science ®Google Scholar
• Gao C, Dimitrov T, Yong KJ, Tatetsu H, Jeong H, Luo HR, Bradner JE, Tenen DG, Chai L. Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex. Blood 2013;121(8):1413–21. doi:10.1182/blood-2012-04-424275.
   PubMed Web of Science ®Google Scholar
• Kollman C, Maiers M, Gragert L, Müller C, Setterholm M, Oudshoorn M, Hurley CK. Estimation of HLA-A, -B, -DRB1 Haplotype Frequencies Using Mixed Resolution Data from a National Registry with Selective Retyping of Volunteers. Hum Immunol. 2007;68(12):950–8. doi:10.1016/j.humimm.2007.10.009.
   PubMed Web of Science ®Google Scholar
• Cao D, Humphrey PA, Allan RW. SALL4 is a novel sensitive and specific marker for metastatic germ cell tumors, with particular utility in detection of metastatic yolk sac tumors. Cancer 2009;115(12):2640–51. doi:10.1002/cncr.24308.
   PubMed Web of Science ®Google Scholar
• Miller G. Immortalization of human lymphocytes by Epstein-Barr virus. Yale J Biol Med. 1982;55(3):305–10.
   PubMed Web of Science ®Google Scholar
• Jeong H-W, Cui W, Yang Y, Lu J, He J, Li A, Song D, Guo Y, Liu BH, Chai L. SALL4, a stem cell factor, affects the side population by regulation of the ATP-binding cassette drug transport genes. PloS One 2011;6(4):e18372. doi:10.1371/journal.pone.0018372.
   PubMed Web of Science ®Google Scholar
• Oikawa T, Kamiya A, Zeniya M, Chikada H, Hyuck AD, Yamazaki Y, Wauthier E, Tajiri H, Miller LD, Wang XW, et al. Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers. Hepatol. 2013;57(3):1469–83. doi:10.1002/hep.26159.
   PubMedGoogle Scholar
• Chevaleyre C, Benhamouda N, Favry E, Fabre E, Mhoumadi A, Nozach H, Marcon E, Cosler G, Vinatier E, Oudard S, et al. The Tumor Antigen Cyclin B1 Hosts Multiple CD4 T Cell Epitopes Differently Recognized by Pre-Existing Naive and Memory Cells in Both Healthy and Cancer Donors. J Immunol. 2015;195(4):1891–901. doi:10.4049/jimmunol.1402548.
   PubMed Web of Science ®Google Scholar
• Su LF, Kidd BA, Han A, Kotzin JJ, Davis MM. Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults. Immunity. 2013;38(2):373–83. doi:10.1016/j.immuni.2012.10.021.
   PubMed Web of Science ®Google Scholar
• Campion SL, Brodie TM, Fischer W, Korber BT, Rossetti A, Goonetilleke N, McMichael AJ, Sallusto F. Proteome-wide analysis of HIV-specific naive and memory CD4(+) T cells in unexposed blood donors. J Exp Med. 2014;211(7):1273–80. doi:10.1084/jem.20130555.
   PubMed Web of Science ®Google Scholar
• Leight ER, Sugden B. EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus. Rev Med Virol. 2000;10(2):83–100. doi:10.1002/(SICI)1099-1654(200003/04)10:2%3c83::AID-RMV262%3e3.0.CO;2-T.
   PubMed Web of Science ®Google Scholar
• Van Zuylen WJ, Rawlinson WD, Ford CE. The Wnt pathway: a key network in cell signalling dysregulated by viruses. Rev Med Virol. 2016;26(5):340–55. doi:10.1002/rmv.1892.
   PubMed Web of Science ®Google Scholar
• Everly DN, Kusano S, Raab-Traub N. Accumulation of cytoplasmic beta-catenin and nuclear glycogen synthase kinase 3beta in Epstein-Barr virus-infected cells. J Virol. 2004; 78(21):11648–55. doi:10.1128/JVI.78.21.11648-11655.2004.
   PubMed Web of Science ®Google Scholar
• Böhm J, Sustmann C, Wilhelm C, Kohlhase J. SALL4 is directly activated by TCF/LEF in the canonical Wnt signaling pathway. Biochem Biophys Res Commun. 2006; 348(3):898–907. doi:10.1016/j.bbrc.2006.07.124.
   PubMed Web of Science ®Google Scholar
• Fan H, Cui Z, Zhang H, Mani SK, Diab A, Lefrancois L, Fares N, Merle P, Andrisani O. DNA demethylation induces SALL4 gene re-expression in subgroups of hepatocellular carcinoma associated with Hepatitis B or C virus infection. Oncogene. 2017;36(17):2435–45 doi:10.1038/onc.2016.399.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Celis E. Peptide epitope identification for tumor-reactive CD4 T cells. Curr Opin Immunol. 2008;20(2):221–7. doi:10.1016/j.coi.2008.04.011.
   PubMed Web of Science ®Google Scholar
• Godet Y, Fabre E, Dosset M, Lamuraglia M, Levionnois E, Ravel P, Benhamouda N, Cazes A, Pimpec-Barthes FL, Gaugler B, et al. Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response. Clin Cancer Res. 2012;18(10):2943–53. doi:10.1158/1078-0432.CCR-11-3185.
   PubMed Web of Science ®Google Scholar
• Casati C, Dalerba P, Rivoltini L, Gallino G, Deho P, Rini F, Belli F, Mezzanzanica D, Costa A, Andreola S, et al. The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res. 2003;63(15):4507–15.
   PubMed Web of Science ®Google Scholar
• Mehrotra S, Britten CD, Chin S, Garrett-Mayer E, Cloud CA, Li M, Scurti G, Salem ML, Nelson MH, Thomas MB, et al. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer. J Hematol Oncol 2017;10(1):82–95. doi:10.1186/s13045-017-0459-2.
   PubMed Web of Science ®Google Scholar
• Fenstermaker RA, Ciesielski MJ, Qiu J, Yang N, Frank CL, Lee KP, Mechtler LR, Belal A, Ahluwalia MS, Hutson AD. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunol Immunother. 2016; 65(11):1339–52. doi:10.1007/s00262-016-1890-x.
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Celis E. Peptide epitope identification for tumor-reactive CD4 T cells. Curr Opin Immunol. 2008;20(2):221–7. doi:10.1016/j.coi.2008.04.011.
   PubMed Web of Science ®Google Scholar
• Godet Y, Desfrançois J, Vignard V, Schadendorf D, Khammari A, Dreno B, Jotereau F, Labarrière N. Frequent occurrence of high affinity T cells against MELOE-1 makes this antigen an attractive target for melanoma immunotherapy. Eur J Immunol. 2010;40(6):1786–94. doi:10.1002/eji.200940132.
   PubMed Web of Science ®Google Scholar